When you decide to start your patient on treatment with UPTRAVI®, it’s important to set goals and expectations with them.
Before starting UPTRAVI®, remind them of the following:
- Anticipate a call from your specialty pharmacy to alert you of your next shipment of UPTRAVI®
- Do not change your dose or stop taking UPTRAVI® unless your doctor tells you to do so1
- Understand expectations for potential side effects. Follow up with your doctor if you have side effects that you cannot tolerate1
- Try to take UPTRAVI® with food. This may help you tolerate the dose better if you are having side effects with UPTRAVI®1
- After the dose adjustment phase, you will have found your personal maintenance dose of UPTRAVI®. This will be the dose you continue to take on a regular basis, unless your doctor tells you otherwise1
UPTRAVI® Dose Adjustment Phase—Helps Meet Individual Patient Needs1
Your patient's recommended starting dose is 200 mcg twice daily. UPTRAVI® dosing is unique to each patient based on how their body responds and adjusts to treatment. The dose adjustment phase is how you find your patient's personal maintenance dose.
*Once daily for patients with moderate hepatic impairment (Child-Pugh class B) and co-administration with moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox, and teriflunomide). Increase in increments of 200 mcg once daily at weekly intervals.
- If a dose of UPTRAVI® is missed, patients should take the missed dose as soon as possible unless the next dose is within the next 6 hours
- If treatment is missed for 3 days or more, restart UPTRAVI® at a lower dose and then retitrate
After the dose adjustment phase1
Once each patient reaches their personal dose (maintenance), a single-tablet equivalent is prescribed BID. There are 8 different single-tablet strengths of UPTRAVI®, each a unique color.
UPTRAVI® OFFERS A RANGE OF DOSE STRENGTHS TO ACCOMMODATE EACH PATIENT’s personal MAINTENANCE dose
UPTRAVI® Offers Oral Administration With Similar Efficacy at Every Dose Group1
Time to first disease progression event in GRIPHON by dose group3
Efficacy by dose group of UPTRAVI® vs placebo3†:
- 40% RISK
REDUCTION(low dose:
200 mcg to 400 mcg)
HR 0.60 (95% CI: 0.41, 0.88) - 47% RISK
REDUCTION(medium dose:
600 mcg to 1000 mcg)
HR 0.53 (95% CI: 0.38, 0.72) - 36% RISK
REDUCTION(high dose:
1200 mcg to 1600 mcg)
HR 0.64 (95% CI: 0.49, 0.82)
UPTRAVI® doses were achieved across the 3 prespecified groups in the GRIPHON trial‡
- 200 mcg to 400 mcg BID (low dose): 23% of patients (n=133)
- 600 mcg to 1000 mcg BID (medium dose): 31% of patients (n=179)
- 1200 mcg to 1600 mcg BID (high dose): 43% of patients (n=246)
ORALADMINISTRATION
- Twice-daily dosing1
- No needles, pumps, or inhalers1§
